Drugs / ZYN002
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06930872 | Jun → Oct 2025 | — | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05149898 | Feb 2020 → Nov 2022 | 22q11.2 deletion syndrome | Harmony Biosciences Management, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03614663 | Jun 2018 → Jun 2020 | fragile X syndrome | Zynerba Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYN002 | “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ |
| Known as | Cannabidiol | “DESIGN: CONNECT-FX was a double-blind, randomized phase 3 trial assessing efficacy and safety of ZYN002, transdermal cannabidiol gel, for the treatment of behavioral symptoms...” PMID 36434514 ↗ Nov 20221“cannabidiol (CBD) administered as ZYN002” NCT05149898 ↗ |
| Known as | CBD | “cannabidiol (CBD) administered as ZYN002” NCT05149898 ↗ |
| Route | Other | “ZYN002 (transdermal)” NCT06930872 ↗ |